Postmortem studies show that 30% of patients dying of malignant disease have metastatic invasion of the lungs,'
and in half of these the lung is the only site of distant spread.2 Life expectancy after detection ot pulmonary metastases is about 12 months, and in most cases a solitary metastasis is rapidly followed by others. The appearance of a solitary opacity on the chest radiograph of a patient with cancer represents a metastasis in abou-80%1M of cases, compared with 1 % if there is no history of cancer.rPatients who can be rendered free of disease at thoracotomy have longer postoperative survival than those with unresectable disease. 4 The advent of effective chemotherapy led to a phase of treating patients with pulmonary metastases with chemotherapy alone without considering the possibility of surgical treatment. This fashion persisted despite the fact that a consistent 15-30% five year survival rate had been reported in many series over the last 50 years in selected patients undergoing pulmonary metastasect-omy for various different tumour types. The survival compares favourably with that expected after resection of a primary lung tumotlr. Surgical resection was offered previously only to It is well established that the disease free interval correlates with survival in certain tvpes of tunour. Patients with pulmonary metastases from soft tissue sarcoma and a disease free interval ot more than 12 months have a significantly longer surviva (median 2-months) than patients with disease free intervals of 12 months or less (median 12 6 months).8 The prognosis for other cancers, such as tumours of the breast and colon and osteogenic sarcoma, may not be related to the disease free interval, confirming the differences in biological behaviour between histologically distinct tumours. The importance of the disease free interval in patients with soft tissue sarcomas is seen when pulmonary metastases detected concurrently with diagnosis of the primary tumour are considered. Putnum Postoperative whole brain radiotherapy has been routinely used as adjuvant treatment after surgical resection but there have been no randomised trials comparing this combination with surgery alone. Radiotherapy seems to improve control ofthe cerebral disease, but evidence that it improves overall survival is lacking. At the very least adjuvant radiotherapy would appear to prolong time to neurological relapse22 and there is some evidence that it reduces the risk of any neurological relapse.20 23 
